The process involves (i) craniotomy for maximum safe resection of the glioblastoma, (ii) ex-vivo treatment of the tumor with an anti-sense oligodeoxynucleotide against insulin-like growth factor 1 receptor followed by irradiation, (iii) placement of the treated tumor in multiple bio-diffusion chambers, which are implanted into the patient’s abdominal sheath to elicit an immune response, and (iv) explantation of the chambers 48 hours later. Here, IGF1R is linked to neoplasm.